Troculeucel for alzheimer disease

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 30 Jun 2025: Trial started, NCT07228078
  2. 13 Nov 2025: Trial registered, NCT07228078

The trials

NCT07228078: Open-Label Extension Protocol to SNK01-AD01 Study

State
Under way
Phase
Phase 2
People
30 planned
Started
30 Jun 2025
Primary completion
Apr 2028
Arms
Open-Label
Results
None posted
  1. 30 Jun 2025: Trial started
  2. 13 Nov 2025: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.